<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94079">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895855</url>
  </required_header>
  <id_info>
    <org_study_id>PXVX-VC-200-003</org_study_id>
    <nct_id>NCT01895855</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose Live Oral Cholera Vaccine, PXVX0200 CVD 103-HgR, in Preventing Cholera Following Challenge With Vibrio Cholerae 10 Days or 3 Months After Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PaxVax, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PaxVax, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the purpose of the study is to determine if PXVX0200 is safe and effective in preventing
      cholera infection
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Ten day cholera challenge</measure>
    <time_frame>Ten days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine whether a single dose of PXVX0200 provides significant protection against a challenge with virulent V. cholerae O1 El Tor Inaba at 10 days after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ninety day cholera challenge</measure>
    <time_frame>Ninety days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine whether a single dose of PXVX0200 provides significant protection against a challenge with virulent V. cholerae O1 El Tor Inaba at 3 months after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease severity</measure>
    <time_frame>from vaccination through day 180</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total weight of diarrheal stools Incidence of diarrhea of any severity Incidence of fever Incidence of fecal shedding of wild type Vibrio cholerae Peak concentration of wild type Vibrio cholerae detected in stool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerability of vaccine</measure>
    <time_frame>following vaccination through 180 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, and fever Incidence and severity of unsolicited adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Cholera</condition>
  <arm_group>
    <arm_group_label>PXVX0200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Biological: Placebo physiological saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PXVX0200</intervention_name>
    <description>Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension</description>
    <arm_group_label>PXVX0200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy men or women,

          -  age 18 to 45 years inclusive;

          -  normal medical history and physical examination; and

          -  no clinically significant abnormalities from:

               -  urine dipstick for glucose,

               -  protein, and

               -  blood,

               -  complete blood count,

               -  serum hepatic transaminases,

               -  total bilirubin (direct if abnormal),

               -  creatinine,

               -  electrolytes,

               -  albumin, or

               -  electrocardiogram.

          -  Women must have a negative pregnancy test.

        Exclusion Criteria:

          -  travel to a cholera endemic area in the previous 5 years;

          -  abnormal stool pattern or regular use of laxatives;

          -  history of eating disorders (such as bulimia), anal or rectal disorders, allergy to
             tetracycline and/or ciprofloxacin;

          -  history of cholera or enterotoxigenic E. coli challenge;

          -  current or recent antibiotic use;

          -  pregnancy or nursing;

          -  positive serology for HIV, hepatitis B antigen, or hepatitis C;

          -  any immunosuppressive medical condition;

          -  history of hospitalization for psychiatric illness or use of specific psychiatric
             drugs.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children'S Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>July 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholera</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
